(INNS)
SUCIRASLIMAB(INND)
SUCIRASLIMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS CD22 (SIALIC ACID BINDING IG-LIKE LECTIN 2, SIGLEC2, SIGLEC-2, B-LYMPHOCYTE CELL ADHESION MOLECULE, BL-CAM, LEU-14)], CHIMERIC MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN CHIMERIC (1-453) [VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV5-12-1*01 (96.9%) -(IGHD) -IGHJ3*01 (100%)/HOMO SAPIENS IGHV3-11*01 (79.4%) -(IGHD) -IGHJ4*01 (92.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -HOMO SAPIENS IGHG1*03 (100%), G1M3, NG1M1 (CH1 R120 (220) (124-221), HINGE 1-15 (222- 236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452- 453)) (124-453)], (226-214')-DISULFIDE WITH KAPPA LIGHT CHAIN CHIMERIC (1'-214') [V-KAPPA MUSMUS/HOMSAP...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
SUCIRASLIMABUM(INN)